Antiproteinuric effect of recombinant human erythropoietin (rHuEPO) in predialysis chronic kidney disease (CKD) patients: multicenter observational study

UMIN ID: UMIN000001634

Registered date:14/01/2009

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: Predialysis CKD patients treated with recombinant human erythropoietin (rHuEPO)
• Date of first enrollment: 2009/01/01
• Target sample size: 50
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: Reduction in proteinuria
• Secondary Outcome: Correlation between reduction in proteinuria and increase in Hb.

Key inclusion & exclusion criteria

• Age minimum: Not applicable
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: Patients with cancer, liver cirrhosis, maintenance dialysis and pregnancy were excluded. Patients who were started or changed with antihypertensives or diuretics or who required admission within 6 months before- and after- rHuEPO initiation.

Related Information

• Primary Sponsor: Osaka General Medical Center Department of Kidney Disease and Hypertension
• Secondary Sponsor: Osaka University Hospital
• Source(s) of Monetary Support: None